Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Noxiptiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.63 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 6/20 | 0.63 |
| ▸ | HRH1 | P35367 | 6/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.63 |
| ▸ | HTR2B | P41595 | 5/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.63 |
| ▸ | DRD2 | P14416 | 4/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.63 |
| ▸ | HTR2A | P28223 | 4/20 | 0.63 |
| ▸ | HTR2C | P28335 | 4/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.63 |
| ▸ | DRD3 | P35462 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amitriptyline SCHEMBL3897883 | 0.84 | SLC6A2 (0.81) | SLC6A2LMNAHRH1CYP3A4CYP1A2 | |
| Noxiptiline SCHEMBL29358436 | 0.83 | HTR3A (0.52) | SLC6A2LMNAHRH1CYP3A4CYP1A2 | |
| Noxiptiline SCHEMBL49824 | 0.83 | HTR3A (0.52) | SLC6A2LMNAHRH1CYP3A4CYP1A2 | |
| Noxiptiline SCHEMBL1649695 | 0.82 | HTR3A (0.51) | SLC6A2LMNAHRH1CYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL1286980 | 0.79 | SLC6A2 (1.00) | SLC6A2LMNAHRH1CYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL29362430 | 0.79 | SLC6A2 (1.00) | SLC6A2LMNAHRH1CYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL34527 | 0.79 | SLC6A2 (1.00) | SLC6A2LMNAHRH1CYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL7158809 | 0.78 | SLC6A2 (0.97) | SLC6A2LMNAHRH1CYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL29751879 | 0.78 | CYP3A4 (1.00) | SLC6A2LMNAHRH1CYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL41329 | 0.78 | CYP3A4 (1.00) | SLC6A2LMNAHRH1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108025008-A | Compositions and methods for treating substance use disorders, addiction and psychosis | 安比拉神经疗法公司 | 2018-05-11 | — | — | CN | disclosed |